Boundless Bio, Inc. (BOLD) Stock AnalysisBOLDStock AnalysisBoundless Bio, Inc.

Boundless Bio, Inc. is a clinical-stage oncology company, which is engaged in cancer therapeutics that address the unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA). Using its proprietary Spyglass platform, it identifies targets essential for ecDNA functionality in oncogene amplified cancer cells, then designs and develops small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets. The Company’s lead therapeutic candidate ecDTx, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. BBI-355 demonstrated CHK1 inhibition and tumor regressions in oncogene amplified preclinical cancer models, including those enabled by ecDNA, and is being studied in a first-in-human, Phase I/II clinical trial in patients with oncogene amplified cancers. Its next program is directed at a previously undrugged kinesin target. It operates in the Healthcare sector.

Boundless Bio Inc (BOLD) is currently not a strong buy due to its recent performance and financial instability. The stock is trading at $2.83, with a 5-day change of -5.67% and a year-to-date change of +131.97%. However, the RSI is at 39.906, indicating it is nearing oversold territory, which could suggest a potential rebound. The main risk is the negative earnings trend, with the last reported EPS at -1.06 and a forward P/E of 0, reflecting uncertainty in profitability.

7 analysts cover BOLD: 5 rate it Buy, 2 Hold and 0 Sell. The average price target is 4.00.